Searches / Arzneimittel-Forschung[JOURNAL]

Arzneimittel-Forschung[JOURNAL]

Sun 200 papers
RSS

Leave-one-out procedure in the validation of elimination rate constant analysis.

Grabowski T, Jaroszewski JJ, Sasinowska-Motyl M

Arzneimittelforschung · 2012 Dec · PMID 23203545 · Publisher ↗

Many registration agencies and other organizations define how to calculate the elimination rate constant (kel) value. No validation procedures have been introduced to verify the correct selection of the concentration-tim... Many registration agencies and other organizations define how to calculate the elimination rate constant (kel) value. No validation procedures have been introduced to verify the correct selection of the concentration-time (C-T) points used for the kel calculation. The purpose of this paper is to discover whether kel analysis can be subjected to the condensed validation procedure and what acceptance criteria should be adopted for such a procedure. For the analysis, data collected during bioequivalence studies of 4 drugs were selected, including 2 highly lipophilic drugs (itraconazole, atorvastatin) and 2 weakly lipophilic drugs (trimetazidine, perindopril). Pharmacokinetic calculations were performed with the use of WinNonlin Professional v 5.3. Internal validation of the kel analysis using leave-one-out cross-validation was performed. The present analysis proves that the C-T selection process for the kel calculations cannot be automated. In each of the analysed data series there were such C-T sequences that did not meet even one of the validation criteria. This paper proposes 3 validation criteria which need to be met in order to confirm the optimal selection of C-T data to calculate kel: Q 2≥0.6, R2≥ 0.85, Q 2-R2<0.3, were Q 2 - squared cross-validated correlation coefficient, R2 - coefficient of determination). Application of the validation procedure for the kel analysis under discussion proves the accuracy of the calculations, even if repeated kel analysis is based on a different sequence of points in the elimination phase.

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Yang RX, Ren HX, Zhuang L … +6 more , Gao CL, Dong C, Luo CX, Wang XN, Feng EF, He JC

Arzneimittelforschung · 2012 Dec · PMID 23203544 · Publisher ↗

To evaluate the changes in myocardial enzymes and plasma epirubicin concentration following administration by micro-pump (MP) and intravenous drip (ID) in breast cancer patients.11 self-controlled breast cancer patients... To evaluate the changes in myocardial enzymes and plasma epirubicin concentration following administration by micro-pump (MP) and intravenous drip (ID) in breast cancer patients.11 self-controlled breast cancer patients were recruited for a trial with epirubicin administration by MP for 48 h and by ID for 1 h during 2 cycles of treatment. Plasma concentration of epirubicin at different time points was determined using LC-MS/MS. The levels of myocardial enzymes before and after chemotherapy were compared. Another group of patients receiving epirubicin by ID (n=4) or MP (n=9) were monitored for 4 months.8 patients completed the self-controlled study. The peak concentration of epirubicin in the MP group and the ID group were 21.84±18.85 ng/mL and 294.80±225.54 ng/mL, respectively. The MP group had a longer duration (54~60 h) of plasma concentration of epirubicin not less than 10 ng/mL than that of the ID group (8~14 h). There was significant difference for the alteration of myocardial enzymes before and after chemotherapy (p<0.05) in the ID group, whereas the MP group showed no significant difference (p>0.05). The increased range of myocardial enzymes after chemotherapy in the ID group was larger than that of the MP group and the difference was significant (p<0.05). There is an increased cardiotoxicity in patients receiving epirubicin by ID during the 4-month trial.Administration of epirubicin by MP maintained an effective drug concentration for a longer period of time than by ID. The higher peak plasma concentration observed following epirubicin administration by ID may lead to cardiac toxicity.

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Da YJ, Yuan WD, Zhu LF … +1 more , Chen ZL

Arzneimittelforschung · 2012 Dec · PMID 23203543 · Publisher ↗

Since the first non-peptide Ang II receptor antagonist was originally reported, it has become the most common target in the development of new treatments for hypertension. In recent years, all components of the classical... Since the first non-peptide Ang II receptor antagonist was originally reported, it has become the most common target in the development of new treatments for hypertension. In recent years, all components of the classical RAS have been reported in the prostate, these results suggest the possibility that ARB is a novel therapeutic class of agents for prostate cancer. In this study, a new compound 2-(4-((2-propyl-5-nitro-1H-benzo[d]imidazol-1-yl) methyl)-1H-indol-1-yl) benzoic acid was synthesized and evaluated as a novel angiotensin II AT1 receptor antagonist by radioligand binding assays, anti-hypertensive assays in vivo and oral acute toxicity test. MTT assays and tests in nude mice were used to demonstrate its anti-tumor activity. This new compound showed high affinity to AT1 receptor and anti-hypertensive activity in spontaneously hypertensive rats and renal hypertensive rats. Moreover, in human prostate cancer cells and in athymic nude mice bearing human prostate cancer cells, we observed this new compound had an efficient antiproliferative activity in vitro and anti-tumor activity in vivo. The preliminary pharmacological characteristics with oral acute toxicity test suggested that this new compound can be considered as a candidate for both anti-hypertensive and anti-tumor drug.

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Malekshah RE, Mahjub R, Rastgarpanah M … +5 more , Ghorbani M, Partoazar AR, Mehr SE, Dehpour AR, Dorkoosh FA

Arzneimittelforschung · 2012 Dec · PMID 23196970 · Publisher ↗

Nicotine, the main pharmacologically active component in tobacco and cigarette, has some toxic effects and also high potential for addiction. In this study, the effect of artichoke (Cynara scolymus L.) and zeolite nano-m... Nicotine, the main pharmacologically active component in tobacco and cigarette, has some toxic effects and also high potential for addiction. In this study, the effect of artichoke (Cynara scolymus L.) and zeolite nano-materials on urinary excretion of nicotine and consequently elimination of systematically absorbed nicotine was investigated. A simple, valid and highly sensitive high performance liquid chromatography method has been developed for determination of nicotine in rat urine according to guidelines for bioanalysis.It was found that nano-zeolites can cause increase in urinary concentration of nicotine due to its high surface adsorption. Artichoke leaf extract can cause increase in urinary excretion of nicotine in longer post administration times. It was observed that co-administration of nanozeolites and the leaf extract has the synergetic effect on increasing the urinary excretion of nicotine.

Fluorescence detection of etoposide-loaded nanoparticles by HPLC and pharmacokinetics study.

Yang HZ, Liu L, Xu X

Arzneimittelforschung · 2012 Dec · PMID 23192689 · Publisher ↗

A simple HPLC with fluorescence detection method was developed for determination and pharmacokinetic study of Etoposide in dog plasma.Plasma sample pretreatment involved liquid-liquid extraction of 500 µL plasma. The chr... A simple HPLC with fluorescence detection method was developed for determination and pharmacokinetic study of Etoposide in dog plasma.Plasma sample pretreatment involved liquid-liquid extraction of 500 µL plasma. The chromatographic separation was carried out on a Gemini C18 column with a mixture of methanol (A) and water (B) (0~5 min, volume of A was 45-50%, 5~10 min, volume of A was 50-90%) used as mobile phase at a flow rate of 0.4 ml/min.These results indicated that the accuracy and precision of the current assay were within the recommendations for assay validation as stipulated in "Guidance for Industry: Bioanalytical Method Validation". Etoposide nanoparticles and injection pharmacokinetic parameters were as follows: T1/2, 2.26 (0.71) and 1.74 (0.43) h;Cmax, 13.24 (5.32) and 8.12 (3.61) µg/ml; AUC0-t, 41.32 (7.33) and 16.53 (4.12) µg · ml - 1 · h; AUC0-∞, 49.54 (9.62) and 19.64 (8.22) µg · ml - 1 · h; MRT, 3.13 (0.54) and 2.06 (0.33) h and CL 7.35 (1.53) and 12.61 (2.22), respectively.This method was fully validated and successfully applied to a preclinical pharmacokinetic study of Etoposide in dogs after i. v. drip administration.

Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms.

Yue CS, Scarsi C, Ducharme MP

Arzneimittelforschung · 2012 Dec · PMID 23154888 · Publisher ↗

To better understand the pharmacokinetics and potential advantages of a levothyroxine oral solution vs. tablets and soft gel capsules.4 randomized, 2-treatment, single-dose (600 mcg levothyroxine), 2-way crossover bioequ... To better understand the pharmacokinetics and potential advantages of a levothyroxine oral solution vs. tablets and soft gel capsules.4 randomized, 2-treatment, single-dose (600 mcg levothyroxine), 2-way crossover bioequivalence studies in 84 healthy subjects were analyzed. Samples were collected before dosing and until 48-72 h post-dose to calculate noncompartmental baseline-adjusted pharmacokinetic parameters: maximum concentration, time to maximum concentration, and area-under-the-concentration-time-curve from 0 to 48 h and from 0 to 2 h.Mean pharmacokinetic parameters (±standard deviation) for tablets, capsules and solution, respectively, were: area-under-the-concentration-time-curve from 0 to 2 h (ng*h/mL)=68.4±32.8, 64.4±24.4, 99.1±22.7; area-under-the-concentration-time-curve from 0 to 48 h (ng*h/mL)=1 632±424, 1 752±445, 1 862±439; maximum concentration (ng/mL)=67.6±20.9, 68.0±15.9, 71.4±16.0; time of maximum concentration (hours)=2.25±0.99, 2.38±1.58, 1.96±1.07. Overall rate and extent of exposure were not statistically different between formulations, but a faster onset of absorption for the solution was suggested (greater area-under-the-concentration-time-curve from 0 to 2 h and faster time to maximum concentration by an average of 30 min).Levothyroxine rate and extent of exposure are similar between tested formulations. The solution appears however to reach systemic circulation quicker as dissolution is not needed before absorption starts. The solution's greater early exposure and a faster time to maximal concentration of around 30 min may be of benefit to minimize drug-food interactions and deserves further investigations.

A validated HPLC method for the determination of eriocalyxin B in plasma and its application to pharmacokinetic studies.

Wang Z, Yuan Q, Sun JH … +4 more , Cui Z, Chen HY, Wu H, Chen JX

Arzneimittelforschung · 2012 Dec · PMID 23154887 · Publisher ↗

The purpose of this study was to determine EriB in plasma by using the method of HPLC and collect the preclinical pharmacokinetic parameters of EriB.The analysis involved a simple liquid-liquid extraction. After making a... The purpose of this study was to determine EriB in plasma by using the method of HPLC and collect the preclinical pharmacokinetic parameters of EriB.The analysis involved a simple liquid-liquid extraction. After making alkaline with NaOH, plasma was extracted with diethyl ether and the organic extract was then evaporated. From there, the residue was reconstituted in to the mobile phase. Chromatographic separation was achieved on the C18 column using acetonitrile and 0.1% triethylamine as mobile phase delivered at 1.0 ml/min. The UV detector wavelength was set at 233 nm. Standard curves were linear over the concentration range of 50-2 500 ng/ml.The mean predicted concentrations of the quality control (QC) samples deviated by less than 3% from the corresponding nominal values; the intra-assay and inter-assay precision of the assay were within 10% relative standard deviation. The extraction recovery of EriB was more than 80%.The developed method has been applied to the pharmacokinetic study of EriB in rats.

Synthesis, biological activity and molecular modeling of 4-fluoro-N-[ω-(1,2,3,4-tetrahydroacridin-9-ylamino)-alkyl]-benzamide derivatives as cholinesterase inhibitors.

Szymański P, Markowicz M, Bajda M … +2 more , Malawska B, Mikiciuk-Olasik E

Arzneimittelforschung · 2012 Dec · PMID 23154886 · Publisher ↗

The aim of this study was to synthesize and determine the biological activity of new derivatives of 4-fluorobenzoic acid and tetrahydroacridine towards inhibition of cholinesterases. Compounds were synthesized in condens... The aim of this study was to synthesize and determine the biological activity of new derivatives of 4-fluorobenzoic acid and tetrahydroacridine towards inhibition of cholinesterases. Compounds were synthesized in condensation reaction between 9-aminoalkyl-tetrahydroacridines and the activated 4-fluorobenzoic acid. Properties towards inhibition of acetyl- and butyrylcholinesterase were estimated according to Ellman's spectrophotometric method. Among synthesized compounds the most active were compounds 4a and 4d. These compounds, in comparison with tacrine, were characterized by the similar values of IC50. Among all obtained compounds, 4d presented the highest selectivity towards inhibition of acetylcholinesterase. Molecular modeling studies revealed that all derivatives presented similar extended conformation in the gorge of acetylcholinesterase, however, there were 2 main conformations in the active center of butyrylcholinesterase: bent and extended conformation.

Repeated administration of centhaquin to pregnant rats did not affect postnatal development and expression of endothelin receptors in the brain, heart or kidney of pups.

Briyal S, Lavhale MS, Gulati A

Arzneimittelforschung · 2012 Dec · PMID 23154885 · Publisher ↗

The effect of repeated administration of centhaquin to pregnant rats on postnatal development, and expression of ETA and ETB receptors was determined. Pregnant rats were treated daily with either saline or centhaquin for... The effect of repeated administration of centhaquin to pregnant rats on postnatal development, and expression of ETA and ETB receptors was determined. Pregnant rats were treated daily with either saline or centhaquin for 2 weeks. Male rat pups were sacrificed on day 1, 7, 14 and 28 of birth. Brain, kidney and heart were removed to study the expression of ETA and ETB receptor protein levels. Body weight of pregnant rats increased steadily in both vehicle and centhaquin groups. Expression of ETA receptors in the heart and kidney was similar in vehicle and centhaquin treated postpartum rats, but was significantly increased in the brain of centhaquin treated postpartum rats. No change in expression of ETB receptors was observed. In postnatal rats, mean body weight and weights of the brain, kidney and heart increased proportionally with advancing age and were similar in vehicle and centhaquin groups. The expression of ETA receptors in the brain, heart and kidneys was similar in vehicle and centhaquin groups. ETB receptor expression significantly (p<0.001) decreased by 72% and 70% on day 28 compared to rats of age 1, 7 and 14 days in control and centhaquin groups, respectively. Centhaquin treated rats showed similar expression of ETA and ETB receptors compared to vehicle treatment. This study suggests that repeated administration of centhaquin was well tolerated by pregnant rats that gave birth to normal pups. Centhaquin did not affect postnatal development of rats and had similar expression of ETA and ETB receptors compared to control pups.

Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.

Thappali SR, Varanasi KV, Veeraraghavan S … +2 more , Vakkalanka SK, Khagga M

Arzneimittelforschung · 2012 Dec · PMID 23138519 · Publisher ↗

Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. Methotrexate is an antimetabolite and antifolate drug. Clinical trials utilizing a com... Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. Methotrexate is an antimetabolite and antifolate drug. Clinical trials utilizing a combination of dasatinib and methotrexate in patients with Philadelphia chromosome positive and/or Bcr-Abl positive acute lymphoblastic leukemia are currently ongoing. A need therefore exists to develop a sensitive analytical method for determination of dasatinib and methotrexate in plasma.To estimate methotrexate, dasatinib and its active metabolite N-deshydroxyethyl dasatinib simultaneously using liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) in Wistar rat plasma.The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×3 mm i.d., 4.6 µ) using methanol: 2 mM ammonium acetate buffer, pH 4.0 as mobile phase at a flow rate 1 mL/min in gradient mode. Selective reaction monitoring was performed using the transitions m/z 455.0>175.0, 488.1 > 401.0, 444.26>401.0, and 271.1>- 155.0 to quantify methotrexate, dasatinib, N-deshydroxyethyl dasatinib and tolbutamide respectively.The method was validated over the concentration range of 1-1 000 ng/mL and the lower limit of quantitation was 1 ng/mL. The recoveries from spiked control samples were > 79% for all analytes and internal standard Intra- and Interday accuracy and precision of validated method were within the acceptable limits of < 15% at all concentration.The quantitation method was successfully applied for simultaneous estimation of methotrexate, dasatinib and N- deshydroxyethyl dasatinib in a pharmacokinetic study in Wistar rats.

A parallel design study to assess the bioequivalence of generic and branded hydroxychloroquine sulfate tablets in healthy volunteers.

Liu YM, Chen Q, Zhang MQ … +12 more , Liu GY, Jia JY, Pu HH, Liu Y, Hu CY, Lu C, Wang W, Cao WE, Song B, Song YX, Zhu JM, Yu C

Arzneimittelforschung · 2012 Dec · PMID 23138518 · Publisher ↗

Hydroxychloroquine (HCQ) is a racemic 4-aminoquinoline derivative that was first introduced as an antimalarial, and subsequently applied to the treatment of autoimmune diseases such as rheumatoid arthritis and systemic l... Hydroxychloroquine (HCQ) is a racemic 4-aminoquinoline derivative that was first introduced as an antimalarial, and subsequently applied to the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Information on the pharmacokinetics of HCQ in healthy volunteers, especially in a Chinese population is limited, and this study was conducted to provide support for a generic product to obtain marketing authorization in China.The aim of the present study was to compare the pharmacokinetics and assess bioequivalence of a new generic test and the branded reference hydroxychloroquine sulfate tablets in healthy volunteers.This was a parallel, open-label, randomized, single-dose, 1-period fasting study. 54 healthy subjects were randomly assigned (1:1) to receive 200 mg hydroxychloroquine sulfate tablets of the test or the reference formulation. 15 blood samples were collected and whole blood concentrations of HCQ were determined by a validated liquid chromatography-isotopic dilution mass spectrometry method. Log-transformed Cmax and AUC0-24 values were used to test for bioequivalence. The 2 formulations were considered bioequivalent if 90% confidence intervals (CIs) for the log-transformed ratios of Cmax and AUC0-24 were within the predetermined bioequivalence range of 80-125%. Tolerability was evaluated throughout the study by vital signs, physical examinations, clinical laboratory tests, 12-lead electrocardiograms, and interviews with the subjects about adverse events.54 healthy subjects were enrolled and completed the study (mean [SD] age, height, body weight, and BMI were 23.9 [2.4] years, 168.9 [5.0] cm, 61.3 [5.4] kg, and 21.5 [1.7] kg/m2), 27 subjects per group. No formulation or sequence effects were observed. The mean values of Cmax and AUC0-24 for the test and reference formulations of HCQ (197.6 and 199.0 ng/mL, 2460.1 and 2468.3 ng/mL/h) were not significantly different. The 90% CIs of the ratios of Cmax and AUC0-24 were 99.3% (98.1-102.1%), 99.7% (98.9-101.4%), respectively. 4 subjects (7.41%) experienced a total of 4 mild AEs (headache and microscopic hematuria, 1 each; and increase in plasma triglycerides, 2).The results of this study suggest that the test and reference hydroxychloroquine sulfate tablets are bioequivalent. Both formulations were generally well tolerated.

The effect of ethyl alcohol on the function of spatial memory in rats.

Ratajczak P, Kus K, Jarmuszkiewicz Z … +2 more , Woźniak A, Nowakowska E

Arzneimittelforschung · 2012 Dec · PMID 23115060 · Publisher ↗

Alcoholism is a mental disease in the course of which depression, anxiety, and cognitive function deficits may appear, and these symptoms can be aggravated by comorbid schizophrenia.The aim of this study was to find whet... Alcoholism is a mental disease in the course of which depression, anxiety, and cognitive function deficits may appear, and these symptoms can be aggravated by comorbid schizophrenia.The aim of this study was to find whether spatial memory (Morris Water Maze) function impairment is found in prenatally stressed rats (PSG) (prenatal stress paradigm - animal model of schizophrenia) and whether aripiprazole ARI and olanzapine OLA modify these functions. It was also important to study the effect of ethyl alcohol administered to rats.Behavioural tests showed that ARI and OLA improved spatial memory in the non-stressed control group (NSCG) and in the PSG. Moreover, spatial memory in the non-stressed alcohol group (NSAG) improved significantly compared to the NSCG, while in the prenatally stressed alcohol group (PSAG) spatial memory improved both in comparison to the NSCG and PSG. No statistically significant differences were found by comparing groups which received ethyl alcohol (NSAG, PSAG).

Neuroprotective action and free radical scavenging activity of Guttiferone-A, a naturally occurring prenylated benzophenone.

Nuñez-Figueredo Y, García-Pupo L, Ramírez-Sánchez J … +6 more , Alcántara-Isaac Y, Cuesta-Rubio O, Hernández RD, Naal Z, Curti C, Pardo-Andreu GL

Arzneimittelforschung · 2012 Dec · PMID 23115059 · Publisher ↗

Reactive oxygen species (ROS) are important mediators in a number of neurodegenerative diseases and molecules capable of scavenging ROS may be a feasible strategy for protecting neuronal cells. We previously demonstrated... Reactive oxygen species (ROS) are important mediators in a number of neurodegenerative diseases and molecules capable of scavenging ROS may be a feasible strategy for protecting neuronal cells. We previously demonstrated a powerful iron-chelating action of Guttiferone-A (GA), a naturally occurring polyphenol, on oxidative stress injuries initiated by iron overload. Here we addressed the neuroprotective potential of GA in hydrogen peroxide and glutamate-induced injury on rat's primary culture of cortical neurons and PC12 cells, respectively, and antioxidant properties concerning scavenging and anti-lipoperoxidative activities in cell-free models. The decrease in cell viability induced by each of the toxins, assessed by [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT) assay, was significantly attenuated by GA. In addition, GA was found to be a potent antioxidant, as shown by (i) inhibition of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical reduction (EC50=20.0 μM), (ii) prevention against chemically or electrochemically generated superoxide radicals, (iii) inhibition of spontaneous brain lipid peroxidation and (iv) interference with the Fenton reaction. These results indicate that GA exerts neuroprotective effects against H2O2 or glutamate toxicity and its antioxidant activity, demonstrated in vitro, could be at least partly involved. They also suggest a promising potential for GA as a therapeutic agent against neurodegenerative diseases involving ROS and oxidative damage.

Pharmacokinetics of ginkgolide B injection in beagle dogs.

Song H, Bu F, Wei C … +4 more , Yuan G, Liu X, Wang B, Guo R

Arzneimittelforschung · 2012 Dec · PMID 23093483 · Publisher ↗

A liquid chromatography-mass spectrometry method was developed, validated, and applied to the pharmacokinetic study with doses of 0.68, 2.73 and 10.92 mg/kg of ginkgolide B in beagle dogs after intravenous infusion.An al... A liquid chromatography-mass spectrometry method was developed, validated, and applied to the pharmacokinetic study with doses of 0.68, 2.73 and 10.92 mg/kg of ginkgolide B in beagle dogs after intravenous infusion.An aliquot of blood samples were -collected, separated and quantitatively analyzed by liquid chromatography-mass spectrometry method with mobile phase of acetonitrile-0.02% ammonia solution (33:67, v/v) at a flow rate of 0.8 mL/min on the UltimateTM XB-C18 column (5 μm, 4.6×150 mm).The method was sensitive, accurate and convenient, and can be used for the determination of ginkgolide B in beagle dogs. The Cmax and AUC0-∞ of GB increased with dose escalation, but ANOVA analyses showed that no significant difference was observed in other pharmacokinetic parameters between different doses.An LC/MS method was developed with good sensitivity, reproducibility and specificity. In the pharmacokinetic study of GB in beagle dogs, linear pharmacokinetics was found at doses from 0.62 to 10.92 mg/kg after a single-dose intravenous infusion. Gender differences were not observed in the pharmacokinetics of GB.

LC-MS/MS method for determination of epothilone B in rat plasma and its application in pharmacokinetic study.

Lu HM, Ye M

Arzneimittelforschung · 2012 Dec · PMID 23093482 · Publisher ↗

A simple LC-MS/MS method was developed for determination and pharmacokinetic study of Epothilone B in rat plasma.Plasma sample pretreatment involved a one-step liquid-liquid extraction of 100 µL plasma. The chromatograph... A simple LC-MS/MS method was developed for determination and pharmacokinetic study of Epothilone B in rat plasma.Plasma sample pretreatment involved a one-step liquid-liquid extraction of 100 µL plasma. The chromatographic separation was carried out on a Agilent Zobax SB C18 column with a mobile phase consisting of 10 mmol/L ammonium acetate-acetonitrile (35:65, v/v) at a flow rate of 0.2 mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by SRM via electro spray ionization source with positive mode.The standard curve for Epothilone B was linear over the concentration range of 1-100 ng/mL with a lower limit of quantification of 0.5 ng/mL. The intra- and inter-day precision (relative standard deviation) values were not higher than 15% and the accuracy (relative error) was < 10% at 3 quality control levels. Pharmacokinetic parameters were as follows: t1/2, 3.56 (1.12) h; AUC0-24 h, 295.7 (65.3) ng · h/mL and AUC0-∞, 339.2 (87.4) ng · h/mL, CL, 5.77 (0.67) mL/h; MRT, 7.55 (2.41) h, respectively.This simple, fast and highly sensitive method was fully validated and successfully applied to a preclinical pharmacokinetic study of Epothilone B in rats after i. v. administration.

In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.

Kim YH, Choi KS, Kam SH … +2 more , Lee KH, Park JS

Arzneimittelforschung · 2012 Dec · PMID 23093481 · Publisher ↗

The purpose of the present study was to test a sustained release-tablet newly formulated with synthetic paraffin and compare its bioequivalence to that of the Imdur® Long-Acting tablet, based on the guidelines of the Kor... The purpose of the present study was to test a sustained release-tablet newly formulated with synthetic paraffin and compare its bioequivalence to that of the Imdur® Long-Acting tablet, based on the guidelines of the Korean Food and Drug Administration.Dissolution test was performed in 4 different dissolution media. A LC/MS/MS method of isosorbide 5-mononitrate in human plasma was validated. In vivo bioequivalence tests of the 2 isosorbide 5-mononitrate tablets were performed in both preprandial and postprandial states.A comparative dissolution test gave similar results for both tablets in all dissolution media tested: 40% dissolution in pH 1.2 at 2 h and 80% dissolution in pH 4.0, pH 6.8, or water at 10 h. In a bioequivalence study to compare 2 tablets, the mean total area under the curve (AUCt) and peak concentration (Cmax) in the fasted state were 8 476.0 ng · h/mL and 540.4 ng/mL, respectively, for the Imdur® Long Acting Tablet 60 mg, and 8 701.4 ng · h/mL and 564.2 ng/mL, respectively, for the test tablet. The mean AUCt and Cmax in the fed state were 8 793.5 ng · h/mL and 559.9 ng/mL, respectively, for the Imdur® Long-Acting tablet 60 mg, and 8 639.8 ng · h/mL and 617.9 ng/mL, respectively, for the test tablet. The 90% confidence intervals using log transformed data were within the acceptable range of 0.8 - 1.25.Based on these statistical analyses, we conclude that the test tablet is bioequivalent to the Imdur® Long-Acting tablet 60 mg in both the preprandial and postprandial states.

Interaction of 5-amino-1,3,4-thiadiazole-2-thiol and its violuric acid adduct with Pt(II) - crystals structures, spectroscopic properties and cytotoxic activity.

Kavlakova M, Bakalova A, Momekov G … +1 more , Ivanov D

Arzneimittelforschung · 2012 Dec · PMID 23093480 · Publisher ↗

The coordination properties of Pt(II) with 5-amino-1,3,4-thiadiazole-2-thiol [CAS 2349-67-9] (L 1 ) and its novel violurate adduct (L 2 ), both in solution and in solid state, are studied by means of conventional IR-spec... The coordination properties of Pt(II) with 5-amino-1,3,4-thiadiazole-2-thiol [CAS 2349-67-9] (L 1 ) and its novel violurate adduct (L 2 ), both in solution and in solid state, are studied by means of conventional IR-spectroscopy, single crystal X-ray diffraction and thermal methods. The complex compounds of L 1 and L 2 , with general formulas [Pt(C2H2N3S2)2] and [Pt(C6H4N6S2O3)(Cl)]Cl respectively, are obtained. Quantum chemical calculations of the ligands are performed with a view to obtain electronic structure and optical properties of the ligands L 1 and L 2 , respectively. The cell viability of the ligands and metal complexes on a panel of human tumor cell lines is evaluated.

Ketorolac tromethamine improves the analgesic effect of hyoscine butylbromide in patients with intense cramping pain from gastrointestinal or genitourinary origin.

del Valle-Laisequilla CF, Flores-Murrieta FJ, Granados-Soto V … +2 more , Rocha-González HI, Reyes-García G

Arzneimittelforschung · 2012 Dec · PMID 23093479 · Publisher ↗

The symptomatic treatment of pain associated with spasm of gastrointestinal or genitourinary origin can include the use of spasmolytic agents and/or non-steroidal anti-inflammatory drugs. However, the evidence of a super... The symptomatic treatment of pain associated with spasm of gastrointestinal or genitourinary origin can include the use of spasmolytic agents and/or non-steroidal anti-inflammatory drugs. However, the evidence of a superior effectiveness of combination in comparison with individual drugs is scarce and controversial. A double-blind, randomised, clinical trial study was designed to characterize the analgesic effect and safety of ketorolac and hyoscine butylbromide against hyoscine butylbromide alone in patients with ambulatory acute cramping pain of gastrointestinal and genitourinary origin. 160 patients with a pain level ≥4 in a 1-10 cm visual analogue scale were allocated to receive a fixed dose of ketorolac/hyoscine butylbromide (10 mg/20 mg) or hyoscine butylbromide (20 mg) alone at 6 h intervals, during a 48 h period. Both treatments were similarly effective when compared as a whole or when groups were classified by pain origin. Conversely, when treatments were grouped by pain intensity, ketorolac/hyoscine butylbromide combination showed a significant better pain relief profile than hyoscine butylbromide alone in pain intensity ≥7, but not <7. Data indicate that the oral ketorolac/hyoscine butylbromide mixture could be a better option than hyoscine butylbromide alone in the treatment of some acute intense cramping painful conditions.
← Prev Page 1 of 10 Next →

About

Frequency
Sun
Papers found
200
RSS feed
Subscribe